Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms

Expert Review of Hematology

Volumn 7, Issue 2, 2014, Pages 203-216

  Hasselbalch, Hans C ^a  

^a ROSKILDE HOSPITAL   (Denmark)

Author keywords

Chronic inflammation; comorbidities; essential thrombocythemia; interferon a2; JAK inhibitor; myelofibrosis; polycythemia vera; socioeconomic profile; statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2 INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; PEGINTERFERON ALPHA2B; PIPOBROMAN; RUXOLITINIB;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; COMORBIDITY; CYTOREDUCTIVE SURGERY; DRUG POTENTIATION; EARLY INTERVENTION; ENZYME INHIBITION; HUMAN; INFLAMMATION; METASTASIS; MYCOSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PSORIASIS; REVIEW; SPLENOMEGALY; THROMBOCYTHEMIA; TUMOR VOLUME; VIRUS INFECTION;

CHRONIC DISEASE; COMORBIDITY; HUMANS; HYDROXYUREA; INFLAMMATION; INTERFERON-ALPHA; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PYRAZOLES; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84896384320     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.876356     Document Type: Review

References (109)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355(23):2452-66 (Pubitemid 44903749)
2. Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 2011;12(10): 1597-611
3. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7(9):673-83 (Pubitemid 47327415)
4. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111(3):1686-9 (Pubitemid 351213460)
5. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6
6. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010;363(12): 1189-90
7. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24(6):1128-38
8. Pettit JE, Lewis SM, Nicholas AW. Transitional myeloproliferative disorder. Br J Haematol 1979;43(2):167-84 (Pubitemid 10243276)
9. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk Res 2009;33(1):11-18
10. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7(4):e35631
11. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110(3):840-6 (Pubitemid 47267419)
12. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24(9):1574-9
13. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of essential thrombocythemia, polycythemia vera and myelofibrosis. Expert Rev Hematol 2013; 6(1):49-58
14. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis: a human inflammation model for cancer development? Leuk Res 2012; 37(2):214-20
15. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119(14):3219-25
16. Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013;24:133-45
17. Larsen TS, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013;37(9): 1041-5
18. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761-70
19. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978;2(8102):1219-22 (Pubitemid 9071903)
20. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):22-33
21. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006;19(3): 617-33 (Pubitemid 43863144)
22. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33(4):313-20 (Pubitemid 46878103)
23. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350(2):114-24 (Pubitemid 38056222)
24. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332(17): 1132-6
25. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353(1):33-45 (Pubitemid 41007805)
26. Best PJ, Petitt RM. Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin Proc 1998;73(10):961-3 (Pubitemid 28467697)
27. Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29(29):3907-13
28. Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011;11(3):403-14
29. Arlt MF, Ozdemir AC, Birkeland SR, et al. Hydroxyurea induces de novo copy number variants in human cells. Proc Natl Acad Sci USA 2011;108(42):17360-5
30. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107(2):361-70 (Pubitemid 44036566)
31. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233-45
32. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009;113(22):5394-400
33. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012;120(7):1367-79
34. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7 (Pubitemid 36019639)
35. Demaria S, Pikarsky E, Karin M, et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010;33(4): 335-51
36. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009;50(4):541-50
37. Al Ustwani O, Ford LA, Sait SJ, et al. Myelodysplastic syndromes and autoimmune diseases-case series and review of literature. Leuk Res 2013;37(8):894-9
38. Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011;29(21):2897-903
39. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990;34(4):291-300 (Pubitemid 20223505)
40. Pullarkat V, Bass RD, Gong JZ, et al. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol 2003;72(1):8-12 (Pubitemid 36043743)
41. Rondeau E, Solal-Celigny P, Dhermy D, et al. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol 1983;53(3):467-75 (Pubitemid 13153265)
42. Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95(7):1216-20
43. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100(5):822-8
44. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109(6):2446-52 (Pubitemid 46425887)
45. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128(3):275-90 (Pubitemid 40216149)
46. Vannucchi AM, Guglielmelli P. JAK2 mutation-related disease and thrombosis. Semin Thromb Hemost 2013;39:496-506
47. de Groot L, Posthumus MD, Kallenberg CG, Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest 2010;40(9):835-42
48. Kahlenberg JM, Kaplan MJ. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther 2011;13(1):203
49. Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011; 118(25):6515-20
50. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009;18(7):2068-73
51. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109(1):68-76 (Pubitemid 46120195)
52. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORTI: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013; 31(10):1285-92
53. Mesa RA, Shields A, Hare T, et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res 2013;37: 911-16
54. Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 2013;162(2):229-39
55. Kiladjian J, Gisslinger H, Passamonti F, et al. Health-related quality of life and symptom burden in patients with myelofibrosis in the COMFORT-II study. Haematologica (EHA Annual Meeting Abstracts) 2012;97(s1):0378
56. Price GL, Pohl GM, Xie J, Walgren RA. A retrospective observational comparison of comorbidities between myeloproliferative neoplasm (MPN) patients and matched controls in a commercially insured US population. Blood (ASH Annual Meeting Abstracts) 2011;118(21):3140
57. Davis KL, Price GL, Karve S, et al. Comorbidity burden in elderly persons with non-CML myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Blood (ASH Annual Meeting Abstracts) 2012;120(21):1734
58. Naqvi K, Tanaka M, Garcia-Manero G, et al. Patients' comorbidities and overall survival in primary myelofibrosis (PMF). Blood (ASH Annual Meeting Abstracts) 2011;118(21):5164
59. Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep 2010; 5(1):22-8
60. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33(5):523-30 (Pubitemid 40592168)
61. Jensen MK, de Nully Brown P, Lund BV, et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000;110(1):116-24 (Pubitemid 30625599)
62. Jensen MK, de Nully Brown P, Lund BV, et al. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66(3):143-51 (Pubitemid 32324580)
63. Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. J Intern Med 2007;262(2):145-56 (Pubitemid 47087633)
64. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22(7):1299-307
65. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24(9):1574-9
66. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003;91(4A):9B-13B (Pubitemid 36263243)
67. Lardizabal JA, Deedwania PC. The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep 2011;13(1): 43-50
68. Gonzalez GL, Manrique CM, Sowers JR. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy. J Cardiometab Syndr 2006;1(3):178-83
69. Li YB, Yin JJ, Wang HJ, et al. Effect of simvastatin on expression of transforming growth factor-b and collagen type IV in rat mesangial cells. Pharmacology 2011; 88(3-4):188-92
70. Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 2011; 9(11):1013-33
71. Rotta M, Storer BE, Storb RF, et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010;115(6):1288-95
72. Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res 2006; 30(10):1217-25 (Pubitemid 44223726)
73. Saggini A, Anogeianaki A, Maccauro G, et al. Cholesterol, cytokines and diseases. Int J Immunopathol Pharmacol 2011;24(3):567-81
74. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2013;368(6):576-7
75. Griner LN, McGraw KL, Johnson JO, et al. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol 2013;160(2):177-87
76. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-a. Cancer 2006; 107(3):451-8 (Pubitemid 44107203)
77. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112(8):3065-72
78. Larsen TS, Bjerrum OW, Pallisgaard N, et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008; 87(10):847-50
79. Larsen TS, Moller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009;14(6):331-4
80. Fleischman AG, Aichberger KJ, Luty SB, et al. TNFa facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011; 118(24):6392-8
81. Hasselbalch HC, Larsen TS, Riley CH, et al. Interferon alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 2011;12(3): 392-419
82. Hasselbalch HC. A new era for IFN-a in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4(6):C 637-55
83. Essers MA, Offner S, Blanco-Bose WE, et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature 2009;458(7240):904-8
84. Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood 2013;122(8):1464-77
85. Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood 2013; 121(18):3692-702
86. Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4+ CD25+ Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-a. Blood 2011;118(8): 2170-3
87. Swierczek S, Kelley TW, King KY, et al. Salutary effect of pegylated interferona in PV and ET as evaluated by quantitation of pre-JAK2V617F and JAK2V617F-bearing stem cells and granulocytes and correlation with circulating regulatory T cells and HSC cell cycle status. Blood (ASH Annual Meeting Abstracts) 2012;120(21):807
88. Skov V, Riley CH, Thomassen M, et al. Whole blood transcriptional profiling reveals significant downregulation of HLA class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 2013;54(10):2269-73
89. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354(7): 709-18 (Pubitemid 43247141)
90. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune Cresponses. J Clin Oncol 2006;24(19): 3164-71 (Pubitemid 46638955)
91. Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J Clin Oncol 2011;29(18):e564-5
92. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 2010;16(7):1988-96
93. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012;366(9):844-6
94. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
95. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
96. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010;13(6):394-403
97. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood (ASH Annual Meeting Abstracts) 2010; 116(21):313
98. Verstovsek S, Passamonti F, Rambaldi A, et al. Long-Term efficacy and safety results from a phase II study of ruxolitinib in patients with polycythemia vera. Blood (ASH Annual Meeting Abstracts) 2012; 120(21):804
99. Vannucchi A, Kiladjian JJ, Gisslinger H, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase 3 study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT) [abstract 0373]. Poster presentation at: the European Hematology Association Annual Meeting; 14-17 June 2012; Amsterdam, Netherlands
100. Oikonomou E, Tousoulis D, Siasos G, et al. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 2011;52(1):30-40
101. Farmer S, Horvath-Puho E, Vestergaard H, et al. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol 2013;165(5):603-10
102. Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013;27(11):2187-95
103. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120(6):1202-9
104. Verstovsek S, Mesa R, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologic 2013. [Epub ahead of print]
105. Vannucchi A, Kiladjian J, Cervantes F, et al. Long-term outcomes from a phase III study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis; a three-year update of COMFORT-II [abstract S1111]. Oral presentation at: the European Hematology Association Annual Meeting; 14 June 2013; Stockholm, Sweden
106. Griner LN, McGraw KL, Johnson JO, et al. A mechanistic rationale for the use of statins to enhance JAK inhibitor therapy in MPNs. Blood (ASH Annual Meeting Abstracts) 2011;118(21):2816
107. Wang H, Mehta J, Iqbal U, Mesa RA. Analysis of the impact and burden of illness of myelofibrosis in the US. Blood (ASH Annual Meeting Abstracts) 2012;120(21):972
108. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012;120(7):1409-11
109. El Ouagari K, Knight CJ, Mendelson ET. Cost-effectiveness of ruxolitinib versus best-available therapy for medical treatment of myelofibrosis: Canadian Societal Perspective. Blood (ASH Annual Meeting Abstracts) 2012;120(21):4255